These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 38804196)

  • 41. Can one evaluate bone disease in chronic kidney disease without a biopsy?
    Babayev R; Nickolas TL
    Curr Opin Nephrol Hypertens; 2014 Jul; 23(4):431-7. PubMed ID: 24867672
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Updates in CKD-Associated Osteoporosis.
    Khairallah P; Nickolas TL
    Curr Osteoporos Rep; 2018 Dec; 16(6):712-723. PubMed ID: 30353319
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bone turnover markers: Emerging tool in the management of osteoporosis.
    Shetty S; Kapoor N; Bondu JD; Thomas N; Paul TV
    Indian J Endocrinol Metab; 2016; 20(6):846-852. PubMed ID: 27867890
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bone turnover markers and bone mineral density in healthy mother-daughter pairs from South India.
    Shetty S; Kapoor N; Dian Bondu J; Antonisamy B; Thomas N; Paul TV
    Clin Endocrinol (Oxf); 2016 Nov; 85(5):725-732. PubMed ID: 27497063
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Renal Osteodystrophy or Kidney-Induced Osteoporosis?
    Moe SM
    Curr Osteoporos Rep; 2017 Jun; 15(3):194-197. PubMed ID: 28497212
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chronic kidney disease and bone fracture: a growing concern.
    Nickolas TL; Leonard MB; Shane E
    Kidney Int; 2008 Sep; 74(6):721-31. PubMed ID: 18563052
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Biomarkers of Bone Turnover Identify Subsets of Chronic Kidney Disease Patients at Higher Risk for Fracture.
    Hughes-Austin JM; Katz R; Semba RD; Kritchevsky SB; Bauer DC; Sarnak MJ; Ginsberg C; Shlipak MG; Lima F; Malluche HH; Ix JH
    J Clin Endocrinol Metab; 2020 Aug; 105(8):e2903-11. PubMed ID: 32474604
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Pharmaceutical therapy of bone metabolism disorders in chronic kidney disease mineral bone disorder (CKD-MBD) with special respect to antiresorptive substances].
    Lehmann G; Wolf G
    Z Rheumatol; 2014 May; 73(4):329-34. PubMed ID: 24811357
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bone disease in CKD: a focus on osteoporosis diagnosis and management.
    Miller PD
    Am J Kidney Dis; 2014 Aug; 64(2):290-304. PubMed ID: 24726630
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Traditional and Non-traditional Risk Factors for Osteoporosis in CKD.
    Jørgensen HS; David K; Salam S; Evenepoel P;
    Calcif Tissue Int; 2021 Apr; 108(4):496-511. PubMed ID: 33586002
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Bone turnover marker].
    Miura M; Satoh Y
    Nihon Rinsho; 2015 Oct; 73(10):1649-58. PubMed ID: 26529926
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Using early biomarker data to predict long-term bone mineral density: application of semi-mechanistic bone cycle model on denosumab data.
    Zheng J; van Schaick E; Wu LS; Jacqmin P; Perez Ruixo JJ
    J Pharmacokinet Pharmacodyn; 2015 Aug; 42(4):333-47. PubMed ID: 26123919
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Bone-Vascular Axis in Chronic Kidney Disease: From Pathophysiology to Treatment.
    Vachey C; Candellier A; Toutain S; Mac-Way F
    Curr Osteoporos Rep; 2024 Feb; 22(1):69-79. PubMed ID: 38195897
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Use of bone turnover markers in the management of osteoporosis.
    Jain S; Camacho P
    Curr Opin Endocrinol Diabetes Obes; 2018 Dec; 25(6):366-372. PubMed ID: 30299435
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bone turnover markers for osteoporotic status assessment? A systematic review of their diagnosis value at baseline in osteoporosis.
    Biver E; Chopin F; Coiffier G; Brentano TF; Bouvard B; Garnero P; Cortet B
    Joint Bone Spine; 2012 Jan; 79(1):20-5. PubMed ID: 21724445
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Osteoporosis in patients with chronic renal failure : evaluation and management ? Role of bone biopsy].
    Chatzipetrou V; Gerbaix M; Ferrari S; Trombetti A
    Rev Med Suisse; 2018 Nov; 14(626):2012-2017. PubMed ID: 30422421
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Consensus Statement on the Use of Bone Turnover Markers for Short-Term Monitoring of Osteoporosis Treatment in the Asia-Pacific Region.
    Wu CH; Chang YF; Chen CH; Lewiecki EM; Wüster C; Reid I; Tsai KS; Matsumoto T; Mercado-Asis LB; Chan DC; Hwang JS; Cheung CL; Saag K; Lee JK; Tu ST; Xia W; Yu W; Chung YS; Ebeling P; Mithal A; Ferrari SL; Cooper C; Lin GT; Yang RS
    J Clin Densitom; 2021; 24(1):3-13. PubMed ID: 31010789
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and safety of once-monthly risedronate in osteoporosis subjects with mild-to-moderate chronic kidney disease: a post hoc subgroup analysis of a phase III trial in Japan.
    Sugimoto T; Inoue D; Maehara M; Oikawa I; Shigematsu T; Nishizawa Y
    J Bone Miner Metab; 2019 Jul; 37(4):730-740. PubMed ID: 30523414
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Fragility fracture in the Chronic Kidney Disease (CKD)].
    Fusaro M; Aghi A; Mereu MC; Giusti A
    G Ital Nefrol; 2017 Dec; 34(Nov-Dec):. PubMed ID: 29207223
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Biomarkers for osteoporosis management: utility in diagnosis, fracture risk prediction and therapy monitoring.
    Garnero P
    Mol Diagn Ther; 2008; 12(3):157-70. PubMed ID: 18510379
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.